Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
16.03
-0.17 (-1.05%)
At close: Oct 30, 2026, 4:00 PM EDT
15.98
-0.05 (-0.32%)
After-hours: Oct 30, 2026, 7:56 PM EDT
Summit Therapeutics Employees
Summit Therapeutics had 265 employees as of December 31, 2025. The number of employees increased by 106 or 66.67% compared to the previous year. That makes Summit Therapeutics the 24,796th largest employer in the world and 3,176th in the United States.
Employees
265
Change (1Y)
106
Growth (1Y)
66.67%
Revenue / Employee
n/a
Profits / Employee
-$3,230,525
Market Cap
12.82B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 265 | 106 | 66.67% |
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Jazz Pharmaceuticals | 2,890 |
| Caris Life Sciences | 1,846 |
| Ascendis Pharma | 1,189 |
| BridgeBio Pharma | 1,003 |
| Madrigal Pharmaceuticals | 915 |
| Vaxcyte | 507 |
SMMT News
- 6 days ago - Summit, Lunit announce research agreement to evaluate Lunit SCOPE IO - TheFly
- 6 days ago - Summit’s partner announces results from Phase III HARMONi-GI1 study - TheFly
- 6 days ago - Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China - Business Wire
- 8 days ago - Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development - PRNewsWire
- 8 days ago - Summit Therapeutics, Lunit announces research pact over Lunit SCOPE IO - TheFly
- 8 days ago - Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development - Business Wire
- 10 days ago - Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026 - Business Wire
- 11 days ago - Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer - PRNewsWire